NHS
Calderdale
Clinical Commissioning Group

Commissioning Policy

Treatment (brand name, manufacturer if applicable)	Prednisone M/R (Lodotra: Napp)
For the treatment of	Moderate to severe rheumatoid arthritis in adults
Background	The licensed indication of Lodotra is for the treatment of moderate to severe rheumatoid arthritis in adults particularly when accompanied with morning stiffness.
Commissioning position	• NHS C ***does not routinely commission*** the use of Lodotra (Prednisone M/R) for any indication as there is insufficient data on the cost effectiveness of the drug compared to other drug treatments for the PCT to make an informed decision.
Effective from	01/07/2011
Summary of evidence/rationale	Following appraisal of the available evidence and anticipated costs, NHS C is of the view that there is insufficient data available in relation to the cost effectiveness of Lodotra compared to existing corticosteroid therapies, and other alternative treatments such as DMARDs, to enable the PCT to make an informed commissioning decision.
Date	June 2011
Policy to be reviewed by	June 2013
Contact for this policy	Helen Foster, Medicines Management Lead Helen.Foster@calderdaleccg.nhs.uk